Catalyst Pharmaceuticals Inc
$ 24.88
0.08%
26 Feb - close price
- Market Cap 3,055,602,000 USD
- Current Price $ 24.88
- High / Low $ 25.01 / 23.50
- Stock P/E 14.12
- Book Value 7.47
- EPS 1.76
- Next Earning Report 2026-03-18
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.18 %
- ROE 0.28 %
- 52 Week High 26.58
- 52 Week Low 19.05
About
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
Analyst Target Price
$34.57
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-06 | 2025-05-06 | 2025-02-26 | 2024-11-06 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-08 | 2023-08-09 | 2023-05-10 | 2023-03-15 |
| Reported EPS | 0.42 | 0.41 | 0.45 | 0.44 | 0.35 | 0.33 | 0.19 | 0.31 | -0.29 | 0.53 | 0.26 | 0.22 |
| Estimated EPS | 0.33 | 0.39 | 0.34 | 0.32 | 0.3 | 0.26 | 0.17 | 0.27 | -0.28 | 0.42 | 0.32 | 0.21 |
| Surprise | 0.09 | 0.02 | 0.11 | 0.12 | 0.05 | 0.07 | 0.02 | 0.04 | -0.01 | 0.11 | -0.06 | 0.01 |
| Surprise Percentage | 27.2727% | 5.1282% | 32.3529% | 37.5% | 16.6667% | 26.9231% | 11.7647% | 14.8148% | -3.5714% | 26.1905% | -18.75% | 4.7619% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-18 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.298 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CPRX
2026-02-26 09:51:38
Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX) exhibits a strong technical setup for a potential breakout, according to ChartMill's analysis. The company receives high ratings for both its technical condition (7) and setup quality (9), indicating a confirmed upward trend and a well-defined consolidation phase. This pattern suggests the stock is preparing for its next directional move, making it an attractive prospect for technical investors.
2026-02-25 15:51:38
Catalyst Pharmaceuticals is set to report its fourth-quarter and full-year 2025 financial results, with investors focusing on the expected sequential decline in earnings despite a bullish Wall Street outlook. Analysts anticipate EPS of $0.31 on $141.5 million in revenue, a significant drop from Q3, but maintain a "strong buy" rating with a target price suggesting 43% upside. The company's ability to explain the earnings dip and demonstrate sustainable growth in the rare disease market will be key determinants for investors.
2026-02-24 13:53:02
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced its participation in the Barclays 28th Annual Global Healthcare Conference on Tuesday, March 10, 2026. Rich Daly, President and CEO, and other management team members will present at 3:30 PM ET. A webcast of the presentation will be available on the company's website.
2026-02-24 13:13:13
Catalyst Pharmaceuticals, Inc. announced its participation in the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, in Miami, Florida. President and CEO Rich Daly, along with other management team members, will present at 3:30 PM ET. A webcast of the presentation will be available on the company's website.
2026-02-24 08:03:00
Catalyst Pharmaceuticals, a biopharmaceutical company focused on rare diseases, announced that its President and CEO, Rich Daly, and other management team members will participate in the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. The presentation will be webcast live and a replay will be available, aligning with the company's commitment to improving patient lives and expanding its global footprint.
2026-02-20 09:28:49
Aberdeen Group plc reduced its stake in Catalyst Pharmaceuticals (NASDAQ:CPRX) by 8.2% in Q3, now holding 632,441 shares valued at $12.46 million. Despite some insider selling, institutional investors own 79.22% of the company, and analysts maintain a consensus "Buy" rating with an average target price of $33.20. The biopharmaceutical company, with a market cap of $3.00 billion, focuses on therapies for rare neuromuscular, neurological, and metabolic diseases.
